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Abstract 
The crystal structure of a commercially available form of human recombinant (HR) insulin, Insugen (I), used in the 
treatment of diabetes has been determined to 0.92 Å resolution using low temperature, 100 K, synchrotron X‑ray 
data collected at 16,000 keV (λ = 0.77 Å). Refinement carried out with anisotropic displacement parameters, removal 
of main‑chain stereochemical restraints, inclusion of H atoms in calculated positions, and 220 water molecules, 
converged to a final value of R = 0.1112 and  Rfree = 0.1466. The structure includes what is thought to be an ordered 
propanol molecule (POL) only in chain D(4) and a solvated acetate molecule (ACT) coordinated to the Zn atom only 
in chain B(2). Possible origins and consequences of the propanol and acetate molecules are discussed. Three types of 
amino acid representation in the electron density are examined in detail: (i) sharp with very clearly resolved features; 
(ii) well resolved but clearly divided into two conformations which are well behaved in the refinement, both having 
high quality geometry; (iii) poor density and difficult or impossible to model. An example of type (ii) is observed for 
the intra‑chain disulphide bridge in chain C(3) between Sγ6–Sγ11 which has two clear conformations with relative 
refined occupancies of 0.8 and 0.2, respectively. In contrast the corresponding S–S bridge in chain A(1) shows one 
clearly defined conformation. A molecular dynamics study has provided a rational explanation of this difference 
between chains A and C. More generally, differences in the electron density features between corresponding resi‑
dues in chains A and C and chains B and D is a common observation in the Insugen (I) structure and these effects are 
discussed in detail. The crystal structure, also at 0.92 Å and 100 K, of a second commercially available form of human 
recombinant insulin, Intergen (II), deposited in the Protein Data Bank as 3W7Y which remains otherwise unpublished 
is compared here with the Insugen (I) structure. In the Intergen (II) structure there is no solvated propanol or acetate 
molecule. The electron density of Intergen (II), however, does also exhibit the three types of amino acid representa‑
tions as in Insugen (I). These effects do not necessarily correspond between chains A and C or chains B and D in 
Intergen (II), or between corresponding residues in Insugen (I). The results of this comparison are reported.
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Introduction
A definitive account of the 1.5  Å resolution structure 
(PDB 4INS) of hexagonal porcine insulin, which differs in 
sequence by only one amino acid at B30 (and D30) from 
human insulin ( Fig. 1), was published by Baker et al. [1].
Success in the use of pig insulin to control diabe-
tes ultimately lies in its ability to mimic the activity of 
the human form, which is a consequence of near per-
fect structural isomorphism. However, the use of non-
human forms of insulin to control diabetes is known to 
lead to both allergic reactions and other complications 
resulting from antibody production in some patients [2]. 
For this reason the use of recombinant forms of human 
insulin which have now been developed is becom-
ing more commonplace, on the assumption that their 
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structure–function properties are even more closely 
related to the natural hormone. There are 2 independent 
molecules in the asymmetric unit of the crystal structure 
of hexagonal porcine insulin [1]: molecule 1 comprising 
peptide chains A1 and B1, and molecule 2, comprising 
peptide chains A2 and B2 (the 4 chains are now usu-
ally designated A, B, C and D). Peptide chains A and C 
are identical in sequence, as are chains B and D. Chains 
A and B, and chains C and D are linked by disulphide 
bridges Cys7A–Cys7B, Cys7C–Cys7D, Cys20A–Cys19B 
and Cys20C–Cys19D, respectively. Chain A also has an 
internal stabilizing disulphide bridge Cys6A–CysA11 
and there is a corresponding S–S bridge in chain C, 
Cys6C–CysC11. As shown in Additional file  1: Fig-
ure S1 there are 3 AB and 3 CD dimers in the unit cell 
grouped around a crystallographic threefold axis. In the 
2Zn crystals, three non-crystallographic insulin dimers 
are assembled around two Zn ions on the threefold axis. 
Each Zn ion is coordinated to three symmetry-related 
Nε atoms of HisB10 and to three water molecules. Water 
oxygen atoms (282) were also assigned and included in 
the refinement which converged to a value of R = 0.153 
for 10,119 significant  Iobs(hkl). Seven of the amino acid 
side-chains were assigned less ordered conformations, 
refined with separate atomic coordinate sets and occu-
pancy factors. Commercial human recombinant insu-
lin is now available from several sources. The present 
study describes the ultra-high resolution (0.92  Å) low 
temperature structure of Insugen (I) human recombi-
nant insulin, Fig. 1 and Additional file 1: Figure S2a. The 
unpublished structure of a second recombinant form of 
human recombinant insulin, from Intergen, at the same 
resolution, deposited as structure  3W7Y in the Protein 
Data Base (in June 2013) shows a number of surprising 
differences when compared with the Insugen (I) struc-
ture reported here. These two structures will be referred 
to as Insugen (I) and Intergen (II). The Insugen (I) and 
Intergen (II) 2Zn hexagonal HR insulin structures are 
predominantly isomorphous with that of porcine 2Zn 
insulin [1]. In both of these new structures the A and 
B-chains of molecule 1 are in the T-state [3].
Implications for biological activity
HR insulin, Fig.  1, is currently used by the majority of 
insulin dependent diabetic patients, porcine insulin 
having been phased out some years ago [2]. The safe 
therapeutic use of genetically engineered human insulin 
depends on its structure being absolutely identical to 
that of the natural molecule, thereby reducing the pos-
sibility of complications resulting from antibody pro-
duction. It has been noted that  the use of human 
recombinant insulin  in combination with other drugs 
may blunt the signs and symptoms of hypoglycaemia 
[2]. It has been reported [4] that several regions of the 
insulin molecule are closely related to its biological 
activity. These include: (a) the positions of the Cys resi-
dues that form disulphide bridges; (b) the N-terminal 
(A1–A5) of the A-chain; moreover the hydrophobic 
core of vertebrate insulins contains an invariant isoleu-
cine residue at position A2. Lack of variation may reflect 
this side-chain’s dual contribution to structure and 
function: IleA2 is proposed both to stabilize the A1–A9 
α-helix, see Fig.  4b, and to contribute to a “hidden” 
functional surface exposed on receptor binding. In fact 
GlyA1 and IleA2 are stabilized by a network of aqueous 
H-bonds involving some 18 water molecules in Insugen 
(I) (see “Results”; Additional file 1: Figure S5a). Also in 
“Results”, Additional file  1: Figures S5b, c show similar 
networks in Intergen (II) using the deposited 3W4Y and 
porcine insulin using the deposited 4INS pdb file. Addi-
tional file 1: Figures S5c, d and e show end on views of 
these networks. Substitution of IleA2 by alanine results 
in segmental unfolding of the A1–A8 α-helix, lower 
thermodynamic stability and impaired F binding [5]; (c) 
Fig. 1 Insugen (I) HR insulin: amino acid sequence. In the porcine insulin sequence ThrB30 is mutated to Ala
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C-terminal (A16 and A19–21) regions of the A-chain; 
(d) regions B5–B8, B11–B16 and B23–26 in the B-chain; 
(e) moreover crystallographic analysis of the insulin 
molecule has suggested that the structure comprising 
both ends of the A-chain (GlyA1, GlnA5, ThrA19 and 
AsnA21) plus B-chain residues ValB12, ThrB16, GlyB23, 
PheB24 and PheB25 is important for insulin receptor 
binding [6]; (e) in addition to the invariant cysteines, 
only ten amino acids (GlyA1, IleA2, ValA3, TyrA19, 
LeuB6, GlyB8, LeuB11, ValB12, GlyB23 and PheB24) 
have been fully conserved during vertebrate evolution 
[7]; this observation supports the hypothesis derived 
from alanine-scanning mutagenesis studies that five of 
these invariant residues (IleA2, ValA3, TyrA19, GlyB23, 
and PheB24) interact directly with the receptor and five 
additional conserved residues (LeuB6, GlyB8, LeuB11, 
GluB13 and PheB25) are important in maintaining the 
receptor-binding conformation [7]. Baker et  al. [1] in 
the definitive account of the 1.5  Å X-ray structure of 
2Zn porcine insulin, concluded that the major flexibility 
observed at the A-chain N terminus residues A1–A6, 
and the B-chain C terminus residues B25, B28, B29 and 
B30 may be important for the expression of insulin 
activity, especially in view of the rigidity of the rest of 
the structure. Baker et al. [1] also point out that B25.1 
Phe (PheB25) is turned in towards the A-chain whereas 
B25.2 Phe (PheD25) turns out away from the A-chain. A 
summary of the residues involved in these considera-
tions of biological activity is given below in Fig. 2. Each 
residue of interest has been ranked according to the 
number of times it appears in the discussion: α (men-
tioned 4 times) to δ (mentioned once). Residues left 
blank in Fig.  2 are not thought to affect the biological 
activity. Positionally invariable cysteines forming the 
disulphide bridges have been designated α.1 
1 In the publication of Baker et  al. [1] the pig insulin asymmetric unit is 
defined as: molecule 1 (chains A1, B1) and molecule 2 (chains A2, B2). For 
example residue B25.2 Phe refers to phenylalanine 25 in chain B of mol-
ecule 2. However in the PDB deposition of this structure, 4INS, molecule 
1 is designated by chains A and B, and molecule 2 as chains C and D. All.
pdb files referred to in the present publication follow this later format so 
B25.2 Phe of Baker et  al. becomes PheD25. It should also be noted that 
to the best of our knowledge in this revised format in the deposited pig 
insulin 4INS.pdb, unexpectedly Baker et  al’s molecule 1 corresponds to 
chains C + D, and molecule 2 to chains A + B. This means that in Baker 
et  al’s Figure  12.2, for example, the left protruding Phe residue which is 
supposed to be B25.2 Phe (PheD25) is actually B25.1Phe (PheB25). See 
Supporting Information Figures S6a and S6b produced from the 4INS file 
for further details. A second example of this interchange of chain desig-
nations occurs in Figure 4.12 of Baker et al. [1] which describes ValB12.1 
(ValB12) as having a single conformation and ValB12.2 (ValD12) as having 
two conformations. Inspection of 4INS.pdb however confirms the oppo-
site case with ValB12 having double and ValD12 as having a single con-
formation. From this it seems to be safe to assume that this interchange 
of chain designations is consistent throughout Baker et  al. Comparisons 
made in the present publication assume this to be so.
See also “General comments”, “Peptide side chain elec-
tron density and conformations in Intergen (II) [PDB 
3W7Y]”, “Comments on the solvated propanol in Insugen 
(I)”, “PheB24 and PheB25 in Insugen (I) and Intergen (II)” 
for further discussions of the implications of structure for 
biological activity.
Materials and methods
Materials Insugen (I)
Human recombinant insulin (Insugen-30/70) was sup-
plied by Biocon (India) Ltd. See Additional file  1: Table 
S1a. Human recombinant insulin, Intergen (II) was pro-
duced by the INTERGEN Company and purchased by 
Sakabe [8] from the SEIKAGAKU Company. Details are 
to be found in Additional file 1: Figure S2b. Other chemi-
cals including HCl, zinc acetate, acetone, trisodium cit-
rate and NaOH were purchased from Fisher Scientific 
(UK) and Sigma-Aldrich (UK).
Crystallization
Crystallization of Insugen (I)
The crystals were prepared at room temperature by a 
batch method similar to that of Baker et al. [1], modified 
as follows: 0.01 g of insulin as a fine powder was placed in 
a clean test tube; 1 mL of 0.02 M HCl was added to dis-
solve the protein; on addition of 0.15 mL of 0.15 M zinc 
acetate the solution became cloudy due to precipitation 
of the protein; 0.3 mL of acetone and then 0.5 mL of 0.2M 
trisodium citrate together with 0.8  mL of water were 
added and the solution became clear; the pH was checked 
and increased with NaOH to a pH between 8 and 9 for 
different batches, thus ensuring complete dissolution. It 
was then adjusted to the required value of pH 6.3. If any 
slight turbidity occurred, it was removed by warming the 
solution. The solution was then filtered using a Millipore 
membrane/acetate cellulose acetate filter. This removes 
any nuclei which will encourage precipitation or forma-
tion of masses of small crystals.
The solution was then warmed to 50  °C by surround-
ing the test tube with preheated water in a Dewar. This 
allowed the solution to cool slowly to room temperature. 
The test tube was lightly sealed with cling film; crystals 
formed within a few days and were of a suitable size for 
X-ray diffraction within 2  weeks; the test tube contain-
ing crystals was kept at 4 °C prior to data collection. The 
crystal used for data collection was about 0.2 mm3.
Crystallization of Intergen (II)
The following details were supplied by Sakabe [8]. In 
contrast to the Insugen (I) crystals, Intergen (II) crys-
tals were grown using the vapour diffusion hanging drop 
method at 293 K. The reservoir solution contained 0.1 M 
sodium citrate, and 22% (w/v) DMF, and 0.08% (w/v) zinc 
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chloride, pH 8.67 while the protein solution was insulin, 
Intergen (II) dissolved in 0.02  N HCl to a final concen-
tration of 10  mg/mL. The starting volume of the reser-
voir solution was 1 mL, and the volume of the drop was 
20 μL of protein and reservoir solution in a 1:1 ratio. In 
4 or 5 days, crystals were observed to have formed, and 
after 10 days to 2 weeks, insulin crystals of a size suitable 
for X-ray diffraction studies were present, typically about 
0.5 mm × 0.5 mm × 0.3 mm. The crystal used for 3W7Y 
data collection was about 1.2 mm × 0.7 mm × 0.5 mm 
[8].
X‑ray data collection
Insugen (I) crystal at Diamond Light Source, MX beamline I02
Crystals grown at room temperature were passed 
through a 30% glycerol solution, prepared in mother 
liquor, prior to cryo cooling in liquid nitrogen. Crys-
tals were screened with three test shots, separated by 
45° using 0.5  s exposure and 0.5° oscillation. Data were 
collected at 16,000 keV (λ = 0.77 Å) and 100 K with the 
Pilatus 6  M detector as close to the sample as possible 
(179.5  mm). The EDNA strategy [9] was used to obtain 
a start angle and 180° of data were collected with 0.1° 
oscillation and 0.1  s exposure. The resolution of useful 
diffraction data achieved and used for structure analysis 
was 0.92 Å. The spacegroup is H3 (146) and the unit cell 
is a = b = 81.827 Å, c = 33.849 Å, α = β = 90° γ = 120°. 
Further details can be found in Additional file 1: Table S1.
X‑ray data collection for Intergen (II) crystal at the Photon 
Factory beamline BL‑6C (Ibaraki, Japan)
The following details were supplied by Sakabe [8]. A syn-
chrotron data set to 0.7  Å was collected at the Photon 
Factory beamline BL-6C using wavelength λ = 0.97974 Å. 
Data were measured on a specially designed Weissenberg 
type instrument known as “Galaxy”, employing a fully 
automated high speed imaging plate detector. The detec-
tor comprised a vertically focussing 1 m long bent mirror 
of Pt-coated fused silica at a distance of 21  m from the 
SR source point and 7  m from the focal point. The low 
resolution limit was 50.0 and high resolution limit 0.7 Å; 
the number of reflections observed was 91.73%;  Rmerge 
for  Iobs = 0.05579 for 57006 hkl’s. The resolution of use-
ful diffraction data achieved and used for structure analy-
sis was 0.92 Å [10–14]. The space group is: H3 (146); the 
unit cell is: a = b = 81.120 Å, c = 33.930 Å, α = β = 90° 
γ = 120°.
X‑ray data processing for Insugen (I) crystal
Manual processing of the data was carried out using XDS 
[15] to integrate and Aimless [16] to scale and merge 
intensities. The purpose of manual scaling was to opti-
mise the included data to maximise the final resolution 
to 0.92 Å.
Structure solution and initial refinement
Insugen (I)
Molecular replacement was carried out with the pub-
lished structure 3E7Y as a search model in the program 
MOLREP [17], followed by ten cycles of least squares 
refinement using the program REFMAC [18].
Further details can be found in Additional file 1: Table 
S1.
Presence of Zn in the Insugen (I) Crystal
A fluorescence mca scan, Fig. 3, was carried out to con-
firm the presence of zinc in the crystals.
Model building and further least squares refinement
Insugen (I)
Model inspection and rebuilding were performed using 
the program WinCoot 0.7 [19] and further isotropic 
refinement was carried out with the program PHENIX 
[20]. Water molecules were added at the end of refine-
ment using the automated method provided in PHE-
NIX. Refinement of the Insugen (I) crystal structure was 
continued using the program SHELX-97 interfaced with 
SHELXPRO [21]. This facilitated the overall inclusion of 
Fig. 2 Analysis of residues in the porcine insulin structure of Baker et al. [1] which may be important factors involved in the biological activity. α 
indicates most likely and γ is least likely to be active. The positionally invariable cysteines that form the disulphide bridges are also included as being 
very likely to be involved, rated α
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H atoms and use of anisotropic temperature factors for 
the non-H atoms. For the protein structure H atoms ini-
tially assigned in calculated positions were refined with 
isotropic thermal parameters. H atoms were not assigned 
to the waters. During the course of this phase of the anal-
ysis several residues were observed in the electron den-
sity to have ordered or clear double conformations which 
were built into the structure and their relative occupan-
cies were included in the refinement summing to 1.0. At 
the end of the SHELXPRO refinement the R factor and 
 Rfree (all data) were 0.108 and 0.146, respectively. The 
program MolProbity [22] was used for structure valida-
tion. Inspection of the Ramachandran plot revealed that 
97.53% of the residues are in allowed regions. All coor-
dinates and data have been deposited in the Protein Data 
Bank, with identification code 5E7W. The final statistics 
of refinement are summarized in Table 1.
Model building and further least squares refinement 
for Intergen (II)
The structure for 3W7Y was determined by molecular 
replacement and refined using the program REFMAC [18]. 
Non-hydrogen atoms were refined anisotropically. Several 
residues were modelled as two clear conformers with com-
plementary occupational parameters having a sum of 1.0. 
At the end of the refinement the R factor and  Rfree were 
0.162 and 0.180, respectively. Inspection of the Ramachan-
dran plot revealed that 96.81% of the residues are in the 
allowed regions. All coordinates and data are deposited in 
the Protein Data Bank, with identification code 3W7Y.
Results
General comments
Superficially the ultra-high resolution structure of HR 
insulin (Insugen I), as expected, strongly resembles that 
of 2Zn porcine insulin (see “Introduction”) having an 
asymmetric unit with 2 independent molecules: molecule 
1, comprising peptide chains A and B; and molecule 2, 
comprising peptide chains C and D. Peptide chains A and 
C are identical in sequence, as are chains B and D.
As described below there are significant and interest-
ing differences between the detailed ultra-high resolu-
tion structures of Insugen (I) and Intergen (II) and also 
between the two human recombinant insulin structures 
and the less detailed porcine insulin [1]. For exam-
ple in the porcine insulin structure [1] 289 waters were 
assigned and in Intergen (II) 275. However after intense 
scrutiny and assessment 220 water molecules have been 
included and refined in the Insugen (I) structure. Further 
features of interest in the Insugen (I) structure are: (i) an 
acetate molecule ACT2101 (or simply ACT) has been 
assigned in the neighbourhood of Zn2100 in molecule 1 
and is in fact coordinated with this Zn. This unexpected 
feature is described below and is presumably a conse-
quence of the zinc acetate used in the crystallization 
procedure. The acetate molecule has excellent refine-
ment parameters and geometrical features. To the best 
of our knowledge acetate has not been assigned to any 
other published insulin structure; further evidence for 
this assignment can be found in Additional file  1: Text 
S1 and Figure S3: (ii) a solvated propanol molecule has 
been assigned as described below in detail. The propanol 
molecule POL5001 (or simply POL) forms H-bonds 
with the prominent Oγ1A of ThrD27 located on the A 
conformation of ThrD27 which has two clearly defined 
conformations A and B, of which A has 0.645 occupancy 
and B 0.355 occupancy. POL is also H-bonded to water 
6007. Further evidence for the assignment of propanol 
can be found in Additional file 1: Text S2 and Figure S4. 
There is no evidence of propanol solvate close to ThrB27 
in chain B which has a single fully occupied conforma-
tion (see below). Intergen (II) shows no evidence of 
Fig. 3 Fluorescence spectra collected from a crystal of HR insulin, Insugen (I), to confirm the presence of zinc
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either acetate or propanol in the electron density for the 
deposited 3W7Y structure. To the best of our knowledge 
solvated propanol has not been reported as present in 
any other determined insulin structure. Possible origins 
of the solvated propanol are examined. As discussed 
below other differences occur between the two human 
recombinant insulin crystal structures. Such differences 
may ultimately be of importance with respect to the hor-
monal and biological activities of these synthetic thera-
peutics [2].
Description of the secondary structure regions in Insugen 
(I)
The ultra-high resolution refinement of HR insulin, 
Insugen (1) undertaken in the analysis described above 
has enabled a study of the secondary structure motifs 
in the insulin molecule to be carried out in detail which 
exceeds all previous studies.
Chain A (Fig. 4a)
Helix A1 (Fig. 4a, b)
Helix A1: This involves the first 9 residues GlyA1–
SerA9 and comprises about 2 turns of a distorted 
α-helix. Although GlyA1 involves a bifurcated H-bond 
and its (φ, ψ) values are indeterminate because it is 
N-terminal, this residue does seem to be part of the 
helix. SerA9 is at the C-terminal end of the helix, its side 
chain H-bonding to the peptide N of IleA10. Details are 
in Fig. 4b.
Strand A2 (Fig. 4a)
Strand A2 runs from IleA10–SerA12 forms an anti-
parallel sheet with strand B1 in the B-chain (see below). 
Note there is only one β-bridge, at CysA11.
Helix A3 (Fig. 4a, c): this secondary structure involves 
LeuA13–TyrA19 and is a 7 residue  310 helix. The SerA12 
side-chain caps the N-terminal end of the helix by 
H-bonding to the peptide N of GlnA15, whose side-chain 
in turn forms an H-bond to the N of SerA12. The car-
bonyl of SerA12 forms the first H-bond of the helix, but 
the (φ, ψ) values of SerA12 suggest it is part of the pre-
ceding strand and not this helix.
Strand A4 (Fig.  4a): CysA20 and AsnA21 appear to 
form a mini strand and participate in an anti-parallel 
sheet with strand B4 (Fig. 6a) in the B-chain strand. The 
carbonyl oxygen of TyrA19 forms the first H-bond of the 
strand although it is part of the preceding helix.
Chain C (Fig. 5a)
Helix C1 (Fig.  5a, b): GlyC1–SerC9 form a 9 residue 
2 turn helical structure. The first turn (GlyC1-GluC4) 
is α-helix, but then GluC4 forms a H-bond with SerC9 
(i.e. i to i + 5) creating a much looser turn. Strictly, this is 
Table 1 Data-collection and final refinement statistics
Values in parentheses are for the highest resolution shell
a Rmerge =
∑
hkl
∑
i |Ii(hkl)− �I(hkl)�|/
∑
hkl
∑
i |Ii(hkl)| where  Ii(hkl) and 〈I(hkl)〉 are the observed intensity and mean intensity of related reflections respectively
Insugen (I) (Biocon) Intergen (II) (Intergen)
Space group H3 H3
Unit‑cell parameters a = b = 81.8270 Å a = b = 81.120 Å
c = 33.8490 Å c = 33.930 Å
α = β = 90° α = β = 90°
γ = 120° γ = 120°
VM (Å
3 Da−1) 1.97 1.94
Solvent content (%) 22 (223 waters) 25 (275 waters)
Resolution range (Å) 0.92–13.64 0.92–20.0
No. of measurements 294,902
No. of unique reflections 50,178 54,114
Completeness (%) 100 98.59
Multiplicity 5.0 (4.1) 4.2
Ramerge 0.028 0.05579
I/σ(I)mean 20.2 (4.0)
R factor 0.1112 0.162
Rfree 0.1446 0.180
Residues in allowed regions of Ramachandran plot (%) 97.53 96.81
R.m.s.d. bonds (Å) 0.017 0.006
R.m.s.d. angles (°) 2.65 1.187
All‑atom  Baverage (Å
2) 17.947 14.737
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Fig. 4 a Insugen (I) chain A, secondary structure motifs. b Insugen (I) Helix A1: GlyA1–SerA9. With the exception of side‑chains GlyA1 and IleA2 
which are shown completely, only main chain atoms are shown. H‑bonds are shown as green dotted lines. Compare with Figure S9a which shows 
the same region in porcine insulin [1]. c Insugen (I) Helix A3: LeuA13–TyrA19. H‑bonds are shown as green dotted lines. Main chain atoms only are 
shown. Drawn with Biovia, Discovery Studio 2016 [35]
Fig. 5 a Insugen (I) chain C: secondary structure motifs (compare with Fig. 4a for chain A). b Insugen (I) Helix C1: GlyC1–SerC9. H‑bonds are shown 
as green dashed lines. Main chain atoms only are shown. Compare with Figure S9b which shows the same region in porcine insulin [1]. c Insugen (I) 
chain C Helix C3: LeuC13–TyrC19. H‑bonds are shown as green dashed lines. Main chain atoms only are shown. Drawn with Biovia, Discovery Studio 
2016 [35]
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one turn of π-helix. SerC9 terminates the helix by its side 
chain H-bonding to the peptide N of IleC10.
Strand C2 (Fig. 5a): IleC10–SerC12 form a strand, based 
on the (φ, ψ) values. SerC9 is probably not part of this 
strand as its φ, ψ value is at the edge of the β-strand region 
(φ = −90o,ψ = −164o). The strand extends to SerC12.
Helix C3 (Fig.  5a, c): LeuC13–TyrC19 is a 7 residue 
 310 helix comprising about 2 turns. SerC12 caps the 
N-terminus end with its side-chain forming an H-bond 
with the peptide N of GlnC15, while the side-chain of 
GlnC15 forms an H-bond with the peptide N of SerC12.
Strand C4 (Fig.  5a): CysC20 and AsnC21 comprise 
a mini strand and this forms an anti-parallel sheet with 
strand D4 in the D-chain (see below).
Chain B (Fig. 6a)
Strand B1 (Fig. 6a): This comprises seven residues from 
PheB1 to CysB7, based on (φ, ψ) values. This strand forms 
an anti-parallel sheet with the strand A2 in the A-chain.
Helix B2 (Fig.  6a, b): This extends from GlyB8 to 
CysB19 (12 residues), about 3-turns of α-helix. Note 
GlyB8 does not have helical (φ, ψ) values but does have a 
 310 turn H-bond.
Central Loop B3 (Fig. 6a): There is a type I turn from 
GlyB20–GlyB23 and an open α-turn from CysB19 to 
GlyB23.
Strand B4 (Fig.  6a): In terms of (φ, ψ) values, this 
strand could be considered to extend from PheB24 to 
ThrB30, but in terms of H-bonds in the sheet, it ends at 
LysB26. It forms an anti-parallel sheet with D4. Note that 
strands A4 and C4 are part of this four-strand sheet.
Chain D (Fig. 7a)
Strand D1 (Fig.  7a): Based on (φ, ψ) values this strand 
comprises seven residues from PheD1 to CysD7. It is per-
pendicular to strand C2 but does not form a sheet. There 
is only one H-bond from NH of LeuD6 to CO of CysC6 
of chain C which is part of helix C1.
Helix D2 (Fig. 7a, b): This is a 12 residue α-helix from 
GlyD8 to CysC19. Note CysD7 is part of strand D1, 
GlyD8 does not have helical (φ, ψ) values but does have a 
bifurcated H-bond and CysD19 is helical.
Central Loop D3 (Fig.  7a): The region CysD19–
GlyD23 forms an open-α turn and GlyD20-GlyD23 form 
a type I turn.
Strand D4 (Fig.  7a): This extends from PheD24 to 
TyrD26. It forms a sheet with strand B4 and this sheet 
also comprises strands A4 and C4.
Type I Turn D5 (Fig.  7a, c): This is a type I turn and 
comprises ThrD27, ProD28, LysD29 and ThrD30.
Solvent molecules
Solvated water molecules in Insugen (I)
In the crystallographic asymmetric unit a total of 
220 water molecule positions were assigned by ste-
reochemical inspection and evaluation of the elec-
tron density displayed by WinCoot 0.7 [19]. These 
were included successfully in the ShelxL refinement 
with anisotropic thermal displacement parameters. 
Water H atoms were fixed geometrically. Analysis of 
the hydrogen bonding properties of the water mol-
ecules was carried out using Accelrys Discovery Studio 
3 [23] which enabled H-bond geometry to be tabu-
lated. These results are summarised in Table  2 which 
shows the presence of a variety of H-bond types with 
acceptable molecular geometry involving different 
combinations of side-chain–water interactions and 
water–water interactions. For a given water molecule 
the number of side-chain–water interactions var-
ies from 0 to 7 and the number of water-water inter-
actions from 0 to 5. A total of 285 side-chain–water 
H-bonds and 139 unique water–water H-bonds were 
observed. Figure  8 shows an example of a water mol-
ecule, water 6210, having 4 H-bonds to side-chain 
atoms and 2 H-bonds to other waters (6128 and 6209), 
denoted by type 4,2 in Table 2.
Salt bridges in Insugen (I)
Residues involved in the six salt bridges observed in the 
Insugen (I) structure are listed in Table  3 together with 
the corresponding bridge length.
Figure  9 shows the salt bridge between GLYA1:HOC 
and GLUA4:OE1.
Fig. 6 a Insugen (I) chain B secondary structure motifs. b Chain B 
Helix B2: GlyB8‑CysB19. H‑bonds are shown as green dashed lines. 
Main chain atoms only are shown. Light blue regions correspond to 
residues with double side chain conformations. Drawn with Biovia, 
Discovery Studio 2016 [35]
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Water–side chain interactions in Insugen (I)
Of the 102 amino acid residues in Insugen (I) a total of 
18:2 in both chains A and C; 8 in chain B; and 6 in chain 
D do not form any hydrogen bond interactions with 
solvated water molecules. These residues are as follows:
Fig. 7 a Insugen (I) chain D: secondary structure motifs. b Insugen (I) chain D helix D2. H‑bonds are shown as green dashed white lines. Main chain 
atoms only are shown. c Insugen (I) chain D: type I turn. Main chain atoms only are shown. The H‑bond is shown as a green dashed line. There is no 
corresponding secondary structure element in chain B, Fig. 6a. Drawn with Biovia, Discovery Studio 2016 [35]
Table 2 Types of H-bond involving water and their numbers: W–SC water–side chain, W–W water–water
Eg 3,3 N = 2 (italicized) means that 2 water molecules have a total of 3 hydrogen bonds to side chain atoms plus 3 hydrogen bonds to another water molecule (6 
hydrogen bonds in total)
Type of H‑bond W–SC, W–W 0,1 0,2 0,3 0,4 0,5 1,0 1,1 1,2 1,3 1,4 2,0 2,1 2,2 2,3
Number N 18 19 6 3 1 24 18 27 6 2 7 14 6 6
Type of H‑bond W–SC, W–W 3,0 3,1 3,2 3,3 3,4 4,0 4,1 4,2 4,3 5,0 5,1 6,0 7,0
Number N 8 6 6 2 2 2 6 2 1 1 2 1 1
Fig. 8 Water 6210 hydrogen bonds to two waters and three amino 
acid side‑chains. Drawn with Biovia, Discovery Studio 2016 [35]
Table 3 Insugen (I) residues involved in salt bridge forma-
tion
Residue 1 Residue 2 Distance in Å
GLYA1:H0C GLUA4:OE1 1.94398
ARGB22:HH1 GLUA17:OE2 2.25535
ARGB22:HH2 GLUA17:OE2 2.59606
LYSB29:NZ THRB30:OT2 2.4885
GLYC1:H0C GLUC4:OE1 1.79717
ARGD22:HH1 ASNC21:OT1 2.52927
Page 10 of 26Lisgarten et al. Chemistry Central Journal  (2017) 11:73 
Chain A SerA9 LeuA16
Chain B LeuB11 ValB12 AlaB14 LeuB15 CysB19 GlyB23 PheB24 ThrB30
Chain C IleC2 LeuC16
Chain D LeuD11 ValD12 AlaD14 LeuD15 CysD19 PheD24
When such effects are observed it is possible that the use 
of these harsh high speed experimental conditions have 
both caused and allowed these alternative structures to 
be captured for detailed examination. It is also possible 
that such alternative conformations may have a bearing 
on the biological activity of the protein. As described 
below, the present ultra-high resolution structures of 
human recombinant insulin Insugen (I) and Intergen 
(II) both display several amino acid residues having two 
distinct ordered conformations. As described in detail 
below the same residues are not necessarily affected in 
corresponding protein chains in either the Insugen (I) or 
Intergen (II) structure. Thus, somewhat surprisingly, the 
disordered regions do not match 1:1 between the two 
recombinant structures or between corresponding pro-
tein chains in the same structure. A detailed analysis and 
comparison is given below. It is possible that these struc-
tural features may affect the biological functions of these 
recombinant insulins [2].
Properties of the electron density for Insugen (I) are 
summarised in colour code in Fig.  11a and in further 
detail in Additional file 1: Tables S3a–d.
Insugen (I) chain A The electron density of Insugen (I) 
chain A is of very high quality (mainly blue) with few 
problems associated with fitting the amino acid residue 
structures; only the C-terminal residue N21 exhibits a 
Fig. 9 The salt bridge GLYA1:HOC and GLUA4:OE1 in Insugen (I). 
Relevant distances in Å are indicated. Drawn with Biovia, Discovery 
Studio 2016 [35]
Fig. 10 Structure of the Insugen (I) sequence LeuD11–LeuD15. In 
which only GluD13 forms H‑bonds with solvated water molecules. In 
the Insugen (I) structure only 18 of 102 residues fail to link to solvated 
water molecules. Drawn with Accelrys Discovery Studio 3 [23] [note 
Intergen (II) also displays this H‑bonding in the LeuD11–LeuD15 
sequence]
The table above indicates the 18 residues in Insugen (I) 
which do not form any hydrogen bond interactions with 
solvated water molecules. There are 2 in both chains A 
and C; 8 in chain B; and 6 in chain D. Entries in bold are 
common to two chains, either A and C, or B and D.
The residues common to two chains are in bold: Leu16 
in both chains A and C are without water interactions as 
are Leu11, Val12, Ala 14, Leu15 and Cys 19 in both chains 
B and D. The sequence LeuD11–ValD12–GluD13–
AlaD14–LeuD15 is shown in Fig. 10. GluD13 is the only 
residue in this sequence which forms H-bonds with water 
molecules i.e W6034 with OE2 and W6036 with OE1.
It is of interest to note that 14 of the 18 residues that do 
not associate with solvated water molecules are located in 
α-helical structures. These are: CysA6 (helix A1); LeuA16 
(helix A3); LeuB11, ValB12, AlaB14, LeuB15 and CysB19 
(helix B2); IleC2 (helix C1); LeuC16 (helix C3); LeuD11, 
ValD12, AlaD14, LeuD15 and CysD19 (helix D2).
Survey of the peptide side chain electron density 
and conformations in Insugen (I) and Intergen (II)
Peptide side chain electron density and conformations 
in Insugen (I)
It is well known that ultra-high resolution protein struc-
tures derived from X-ray diffraction data using cryo 
cooled crystals often reveal amino acid residues which 
display more than a single ordered conformation. See 
for example Smith et  al. [24] and Addlagatta et  al. [25]. 
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double conformation with two weak regions of density at 
the end of the chain.
Insugen (I) chain C In contrast chain C exhibits the fol-
lowing characteristics: residues Q5, Y14 and Q15 have 
mainly good density but with some poorly defined regions; 
residues C6 and C11 participating in an S–S bridge, and 
L16 demonstrate clear electron density but correspond-
ing to double residue conformations with good geometry 
(orange). The remaining residues are clearly defined in 
strong electron density (blue).
Insugen (I) chain B The electron density of Insugen (I) 
chain B exhibits the following characteristics: residues 
L11, V12, and E13 and T27 have clear electron density 
with two distinct conformations (orange); residues Q4 
and L17 show mainly clear double conformations but with 
some poor density at the extreme end; residue F25 clearly 
adopts two conformations but both phenyl rings A and 
B occupy very weak regions of density; residues K29 and 
T30 are mainly clear single conformations but with some 
terminal disorder. The remaining residues are clearly 
defined in strong electron density (blue).
Insugen (I) chain D In contrast the electron density of 
Insugen (I) chain D can be described as follows: residues 
F1, V2, Q4, E21 and K29 have overall poorly defined elec-
tron density; residues V12 and V18 have clear double con-
formations (orange); residue T27 is mainly a clear double 
conformation but with some missing terminal density. 
The remaining residues are clearly defined in strong elec-
tron density (blue).
Overall comments on  Insugen (I) For the Insugen (I) 
structure the following points may be considered.
1. Why is chain A so well ordered while the related 
chain C shows a number of double conformations 
and poorly defined residues?
2. Chains B and D both show a number of double con-
formations. Double conformations L11, E13 and R22 
occur only in chain B; the double conformation V18 
occurs only in chain D; double conformations V12 
and T27 occur in both chains B and D. L17, R22, F25 
and T30 are disordered in chain B alone; F1, V2 and 
Q4 are disordered in chain D alone; E21, T27 and 
K29 are disordered in both chain B and D.
Fig. 11 Analysis of the correspondence of amino acid modelling and electron density quality in a Insugen (I) and b Intergen (II) HR insulins. Colour 
codes: blue excellent quality electron density with minimal problems for modelling a clear single conformation, orange clear electron density with 
two distinct conformations modelled, red poorly defined electron density with problems in fitting a meaningful structure, blue + red single confor‑
mation modelled, mainly well‑defined but with some minor problems, orange + red two distinct conformations modelled, mainly well‑defined but 
with some minor problems
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It may be possible to rationalise these differences for 
example via molecular dynamics simulations.
Implications for the biological activity The residues most 
likely to affect biological activity in an adverse way are 
those which display conformational differences between 
the corresponding chains A and C, or between chains B 
and D, particularly with respect to the way the residues 
have been rated in Fig. 2.
It follows that the most likely residues are by virtue of:
1. being disordered: PheB25, and to a lesser extent 
GlnC5, AsnA21, LysB29, LysD29 and ThrB30;
2. exhibiting two clear conformations: CysC6–CysC11, 
LeuB11 and ValB12, and to a lesser extent LeuC16 
and GluB13.
The distribution of these residues in the crystal asym-
metric unit is shown in Fig.  12. They clearly form two 
distinctly concentrated groups possibly related to the 
mode of binding or interaction with the receptor.
Peptide side chain electron density and conformations 
in Intergen (II) [PDB 3W7Y]
Properties of the electron density for Intergen (II) are 
summarised in Fig. 11b.
Intergen (II) chain A The electron density of Inter-
gen (II) chain A is of very high quality with no major 
problems associated with fitting the amino acid residue 
structures and no multiple conformations or other dis-
order.
Intergen (II) chain C In contrast chain C exhibits the fol-
lowing characteristics: residues 1–4, 7, 8, 12, 13, 16,17,19–
21, have clear well defined density; residue Q5 has mainly 
clear density but with missing terminal density; residues 
S9, I10, N18 and C6–C11 are modelled as single confor-
mations but are probably well ordered double conforma-
tions (all shown in orange in Fig. 11b; Y14 has very poor 
electron density and is fitted as Ala; Q15 also has very 
poor density and is disordered).
Intergen (II) chain B Chain B exhibits the following 
characteristics: residue F1 has mainly clear density but 
with missing terminal density; residues 2–10, 13–26 
and 28–30, have clear well defined density; residues 
L11 and V12 are modelled as single conformations 
but are probably well ordered double conformations, 
whereas residue T27 is in clear well defined density 
and is modelled as a double conformation but has miss-
ing terminal density (all three are shown in orange in 
Fig. 11b).
Fig. 12 Distribution of residues possibly associated with receptor binding and biological activity of HR insulin, Insugen (I). The major concentration 
of residues occurs on chain B (blue) which includes the residue Phe25B discussed in the definitive account of the porcine insulin X‑ray structure by 
Baker et al. [1]. In the Insugen (I) structure Phe25B occupies two distinct well defined conformations as shown here. It is of interest to note that in 
Intergen (II) HR insulin Phe25B has a clear well defined conformation. Alternative conformations in Insugen (I) residues are coloured blue here. A 
minor group of residues occurs on chain C (coloured grey). Drawn with Accelrys Discovery Studio 3 [23]
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Intergen (II) chain D Chain D exhibits the following 
characteristics: residues 2,3, 5–11, 13–20, 22–28, and 30 
are all well defined in clear electron density; F1 is in clear 
but weak density; Q4 is largely well defined but has miss-
ing terminal density; V12 is modelled in a clear single con-
formation but is in density that strongly suggests it is dis-
ordered in two clear conformations (orange in Fig. 11b); 
E21 and K29 are poorly defined with weak density that 
does not include all atoms in the residue chains.
Overall comments on Intergen (II) As for the Insugen (I) 
structure the following points can be made for Intergen 
(II). Why is chain A so well ordered while chain C shows a 
number of double conformations and poorly defined resi-
dues? Chain B shows one double conformation. There are 
no double conformations in chain D.
Comparison of the Insugen (I) and Intergen (II) structures
Referring to Fig. 11:
1. Both A-chains have mostly well-defined electron 
density with very few problems in their interpreta-
tion.
2. For the C-chains the only notable difference here lies 
in the assignment of a double conformation for the 
C6–C11 disulphide bridge in Insugen (I). As men-
tioned above the electron density for Intergen (II) 
in this region, Fig. 16, strongly suggests that it might 
be possible to model a double conformation here as 
well.
3. Comparison of the B-chains of Insugen (I) and Inter-
gen (II): differences here occur for residues L11, 
V12 and R22 which have double conformations in 
Insugen (I) and T27 which has a double conforma-
tion in Intergen (II). Insugen (I) chain B also has 
problem residues E13, L17, E21, F25, T27, K29 and 
T30, which are well behaved in Intergen (II). Intergen 
(II) chain B has one residue T27 modelled as a double 
conformation but which is single in Insugen (I).
There are a number of differences between Insugen (I) 
chain D and Intergen (II) chain D. In Insugen (I) F1, V2 
and T27 all have problem electron density but are well 
behaved in Intergen (II); Q4, E21 and K29 have weak 
or poorly defined electron density in both structures; 
residues S9, V12 and V18 have double conformations in 
Insugen (I) but not in Intergen (II).
General comments on Insugen (I) and Intergen (II) structures
The above analysis has indicated that in both the Insugen 
(I) and Intergen (II) structures the sequence equiva-
lent protein chains A and C, and B and D, respectively 
exhibit significant differences with respect to their 
corresponding amino acids such as double conforma-
tions and quality of the electron density. It is of interest 
to note that Baker et al. [1] in discussing the 1.5 Å X-ray 
structure of porcine insulin, report the presence of seven 
disordered amino acid residues: two in chain B (ArgB22 
and LysB29) and five in chain D (GlnD4, ValD12, GluD21, 
ArgD22 and ThrD27). Of these only two amino acids in 
Insugen (I) ArgB22 and ValD12, have double conforma-
tions. The question of double conformations and poorly 
defined or absent electron density in the recombinant 
human insulin structures and the widespread lack of cor-
respondence between the two raises two questions: (1) 
what is the origin of these differences? And (2) do they 
affect the therapeutic properties of these preparations? 
With respect to question (1) the possibilities include (a) 
method of preparation including folding of the recombi-
nant amino acid-chains and (b) the forces in play when 
the crystal is cryo cooled prior to X-ray data collection. 
With respect to question (2) it is well known that differ-
ences in the form of a therapeutic insulin preparation 
with respect to the naturally occurring insulin can induce 
the production of antibodies in patients. No such indica-
tion has been noted with respect to the widespread use 
of either Insugen (I) or Intergen (II) but is nevertheless a 
possibility which should be borne in mind.
Some further selected details
Insugen (I) structure: chain C(3) S–S bridge between Sγ6–Sγ11
The electron density excerpt below, Fig.  13, reveals the 
distinct disordering in this region. This shows the elec-
tron density in the disordered internal S–S bridge of 
Insugen (I) chain C(3) between Sγ6–Sγ11. Atom Sγ11 
occupies two clear sites A (80%) and B (20%). Sγ6 occu-
pies a single site.
Fig. 13 Electron density in the disordered internal S–S bridge in 
Insugen (I) chain C between Sγ6–Sγ11. Atom Sγ11 occupies two 
clear sites A (80%) and B (20%). Sγ6 occupies a single site. Drawn with 
WinCoot 0.3 [19]
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Figure  14a shows details of the Insugen (I) struc-
ture: chain C(3) S–S bridge between Sγ6–Sγ11 show-
ing the geometry of part A of the disordered S–S bridge 
in chain C(3). For Sγ6–Sγ11A: Cα6–Cβ6  =  1.532  Å, 
Cβ6–Sγ6  =  1.815  Å, Sγ6–Sγ11A  =  2.119  Å, Sγ11A–
Cβ11A  =  1.785  Å, Cβ11A–Cα11A  =  1.547  Å; Cα6–
Cβ6–Sγ6  =  114.16°, Cβ6–Sγ6–Sγ11A  =  98.05°, 
Sγ6–Sγ11A–Cβ11A  =  104.10°, Sγ11A–Cβ11A–
Cα11A  =  112.22°; torsion angle χ3  =  Cβ6–Sγ6–Sγ11A–
Cβ11A  =  108.23° corresponds to right handed chirality 
[26].
Figure  14b shows the geometry of part B of the dis-
ordered S–S bridge in chain C(3) for Sγ6–Sγ11B: Cα6–
Cβ6 = 1.532 Å, Cβ6–Sγ6 = 1.815 Å, Sγ6–Sγ11B = 1.966 Å, 
Sγ11B–Cβ11B  =  1.771  Å, Cβ11B–Cα11B  =  1.534  Å; 
Cα6–Cβ6–Sγ6  =  114.16°, Cβ6–Sγ6–Sγ11B  =  112.79°, 
Sγ6–Sγ11B–Cβ11B  =  103.44°, Sγ11A–Cβ11A–
Cα11A  =  114.26°; torsion angle χ3  =  Cβ6–Sγ6–Sγ11B–
Cβ11B = −79.10° corresponds to left handed chirality [26]. 
Additional file 1: Figure S7 shows views of the major and 
minor conformations of this S–S bridge with respect to the 
secondary structure of the protein.
Figure  15a shows the electron density in the ordered 
internal S–S bridge in chain A(1) between Sγ6–Sγ11. 
Compare with Fig.  13 which shows the correspond-
ing S–S bridge in chain C(3) in which atom Sγ11 is dis-
ordered into two sites A (80%) and B (20%) and Fig. 16 
which shows the electron density in this region in Inter-
gen (II) which has been modelled and refined as a single 
ordered cysteine but appears, in fact, to be an ordered 
double conformation as in Intergen (I). 
Figure 15b shows the geometry of the ordered internal 
S–S bridge in Insugen (I) chain A(1) Sγ6–Sγ11: Cα6–
Cβ6 = 1.532 Å, Cβ6–Sγ6 = 1.797 Å, Sγ6–Sγ11 = 2.051 Å, 
Sγ11–Cβ11  =  1.806  Å, Cβ11–Cα11  =  1.533  Å; Cα6–
Cβ6–Sγ6  =  116.37°, Cβ6–Sγ6–Sγ11  =  103.66°, Sγ6–
Sγ11–Cβ11 = 101.86°, Sγ11A–Cβ11A–Cα11A = 113.83°; 
torsion angle χ =  Cβ6–Sγ6–Sγ11B–Cβ11B =  106.49° is 
close to the value of χ = 108.23° in the major conforma-
tion in chain C(3) and again corresponds to right handed 
chirality [26] the minor conformation being left handed, 
χ3 = −79.10°.
Conclusions on the comparison between Insugen (I) 
and Intergen (II) structures
Possible explanations for the observed bifurcation of 
chain C(3) Sγ6–Sγ11 disulphide are as follows: CysC6 is 
hydrogen bonded to a water molecule and there are sev-
eral other waters modelled in this region which may be 
associated with greater conformational flexibility com-
pared to CysA6. In addition CysA6 is in a hydrophobic 
pocket devoid of solvate molecules and consequently the 
disulphide may be more restricted by this environment. 
This is supported by the fact that the section of chain D 
close to chain A(1) Sγ6–Sγ11 disulphide is disordered 
(residues D1, 2 and 4) whereas the section of chain B close 
to chain C(3) Sγ6–Sγ11 disulphide is not, Fig.  11a and 
Additional file 1: Tables S3c, d. In “Molecular dynamics” 
the results of a molecular dynamics study of this observed 
order/disorder in the Sγ6–Sγ11 disulphides are presented.
Intergen (II) structure: chain C(3) S–S bridge between Sγ6–
Sγ11
Inspection of the deposited X-ray structure of Inter-
gen (II) (3W7Y), indicates that no attempt was made to 
model CysC6–CysC11 in chain C in a double conforma-
tion. However the superposition of the refined Insugen 
(I) chain C with the 3W7Y chain C indicates that the 
Fig. 14 a Insugen (I) structure: chain C(3) S–S bridge between Sγ6 and Sγ11 showing the geometry of the major conformation part A of the disor‑
dered S–S bridge in chain C(3). b Insugen (I) structure: chain C(3) S–S bridge between Sγ6 and Sγ11 showing the geometry of the minor conforma‑
tion part B of the disordered S–S bridge in chain C(3). Drawn with Accelrys Discovery Studio 3 [23]
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alternate conformation of the disulphide from residues 
CysC6–CysC11 is likely also to be present, but not mod-
elled, in the 3W7Y structure. This is indicated by the 
presence of negative electron density (green) in the same 
position as the CysC11 γ sulphur atom in the second 
(minor) conformation and positive (red) electron density 
in the over modelled main conformation, Fig. 16.
The possibility of this effect being accounted for by 
radiation damage in the Insugen (I) structure was inves-
tigated by closely inspecting the intensity data collected. 
This led to the conclusion that there is no global sug-
gestion of radiation damage in the data. Next a number 
of subsets of data were integrated and scaled and the 
minimum set of data with acceptable completeness was 
assembled by using images  1–600 (the first third of the 
data). When solved and initially refined there was still 
evidence for the second conformation at this disulphide 
bond. As two clear conformations, rather than complete 
disorder have been assigned successfully it may be con-
cluded that this is a reflection of the true state in the 
crystal, rather than radiation damage. Further examina-
tion of the difference in the disulphides A6–A11 (single 
ordered conformation) and C6–C11 (clear ordered dou-
ble conformation) may be explained by the difference in 
solvent exposure. C6 is less than 4  Å from the nearest 
solvent molecule and there are several waters modelled 
in that area which may give greater conformational flex-
ibility to the region. A6 is in a hydrophobic pocket and 
consequently the disulphide may be more restricted by 
that environment. This is supported both by the fact that 
the section of chain D in this vicinity of the part of the 
molecule is also disordered (see above).
Solvated propanol in Insugen (I)
The ultra-high resolution Insugen (I) X-ray structure 
has been found to include an unexpected solvated pro-
panol molecule (POL5001), Fig.  17a. This solvate forms 
H-bonds with the prominent Oγ1A of ThrD27 in chain 
D(4), water 6002 and water 6007. The electron density 
for this solvate is clear (Fig. 17a) and the geometry of the 
refined propanol is excellent (Fig.  17b). ThrD27 in the 
Insugen (I) structure is cleanly split into two parts A and 
B as can be seen in Fig. 17a. To the best of our knowledge 
no other insulin structure has been shown to include 
structurally ordered propanol.
Figure  17c shows the propanol molecule in Insugen (I) 
lying in a binding pocket formed by rigid body movement 
of the first helix of chain C with respect to the structure of 
Baker et al. [1] (PDB 4INS). Interestingly, there is a similar 
Fig. 15 a Electron density in the ordered internal S–S bridge Insugen 
(I) chain A(1) between Sγ6 and Sγ11. Drawn with WinCoot 0.7 [19]. 
b Insugen (I) structure: chain A(1) S–S bridge between Sγ6 and Sγ11 
showing the geometry of the ordered S–S bridge after refinement. 
Drawn with Accelrys Discovery Studio 3 [23]
Fig. 16 Electron density in Intergen (II) (3W7Y) in the vicinity of the 
disulphide bridge in chain C CysC6–CysC11. The presence of green 
density (arrowed) suggests the existence of a second conformation, 
as in the Insugen (I) structure. This second, minor, conformation has 
not been modelled in deposited Intergen (II) structure. Drawn with 
WinCoot 0.7 [19]
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movement of chain A in spite of there being no propanol 
solvate in this region. The C-terminal of chain D is also 
displaced towards the propanol binding pocket, while on 
chain B the movement is in the opposite direction.
Figure 18a shows the electron density in Insugen (I) in 
the vicinity of ThrB27 in chain B. There is no evidence of 
solvated propanol bound in this site. Similarly Fig.  18b 
shows Intergen (II) in the vicinity of chain D ThrD27 
again with no propanol present, as is also the case for 
Intergen (II) chain B ThrB27.
Comments on the solvated propanol in Insugen (I)
It is interesting to note that Step 12 of US Patent Appli-
cation Number US 13/032,797 [27] describes the use of 
n-propanol in a process for producing improved prepa-
rations and methods for manufacturing substantially liq-
uid preparations of RH insulin API. It is possible that the 
manufacture of Insugen (I) has included a similar step 
and this is the origin of the bound propanol revealed in 
the ultra-high resolution X-ray structure described here. 
Fig. 17 a Insugen (I) COOT electron density in the vicinity of ThrD27. 
Electron density for the solvated propanol 5001 and water 6007 are 
shown. H‑bonds between propanol and Oγ1A of ThrD27 and water 
6007, respectively are indicated. Drawn with WinCoot 0.7 [19]. b 
Detail produced by Discovery Studio 3 (Accelerys) [23, 35] showing 
the solvated propanol in Insugen (I) with respect to OG1A ThrD 27 
and water 6007. c The solvated propanol in Insugen (I) with respect 
to Oγ1A Thr D27 and water 6007. Drawn with Discovery Studio 3 
(Accelerys) [23, 35]
Fig. 18 a Insugen (I) HR insulin: WINCOOT 0.7 [19] electron density in 
the vicinity of ThrB27 in chain B. Unlike the corresponding site ThrD27 
in chain D there is no evidence of solvated propanol in this site. b 
Intergen (II) 3W7Y: WINCOOT 0.7 [19] electron density in the vicinity 
of Thr D27. There is no evidence of solvated propanol in this site. The 
same applies to the Intergen (II) ThrB27 site
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It is possible that the presence of propanol in this insu-
lin preparation may have consequences with respect to 
its biological/therapeutic characteristics [28]. Further 
evidence for the assignment of propanol in this pocket 
of electron density was obtained by modelling in a num-
ber of different likely possibilities. Of these propanol 
emerged as the most likely candidate (see Additional 
file 1: Text S2, Figure S4).
The use of the molecular modelling procedures 
described in “Molecular dynamics” to investigate reasons 
for the presence of propanol in the binding site located 
on chain D of Insugen (I) described here is currently in 
progress.
The Zn sites in molecules 1 and 2
Insugen (I) and Intergen (II) have been synthesised to 
include the Zn ions present in naturally occurring insu-
lins. The Zn ions are an essential feature in the formation 
of the crystal structure and are located on a crystallo-
graphic three-fold axis. In porcine insulin 2 Zn crystals 
[1], three insulin dimers are assembled around two zinc 
ions, 15.82  Å apart on the threefold axis. Each zinc is 
coordinated to three symmetry related Nε atoms of resi-
due His10B, both at 2.05 Å, and to three water molecules 
at 2.36 and 2.21 Å, in molecules 1 (chains A and B) and 2 
(chains C and D), respectively. During the course of the 
X-ray analysis of Insugen (I) the Zn sites in molecules 1 
and 2 were carefully examined.
The Zn site in Insugen (I) molecule 1 The electron density 
in the vicinity of Zn2 in molecule 1 is shown in Fig. 19a. 
This reveals an unexpected feature which was modelled 
and successfully refined as a solvated acetate molecule, 
acetate 2101. Zn2100 is coordinated to both His 2010 Nε 
in chain B and an oxygen atom of acetate2101 (Fig. 19b). 
The geometry of acetate2101 (Fig.  19b) and its refined 
parameters are of excellent quality. Note: the complete 
coordination sphere around the zinc ion is generated by 
application of the crystallographic three-fold symmetry.
The Zn site in Insugen (I) molecule 2 Figure 19c shows 
the electron density in the vicinity of Zn1 in Insugen 
(I) molecule 2. This shows Zn4100 coordinated to His 
4010  Nε and two water molecules. This is the normal 
mode of Zn binding in insulins [1]. Note: as for molecule 
1 the complete coordination sphere around the zinc ion 
is generated by application of the crystallographic three-
fold symmetry.
Additional file  1: Figure S8 shows the arrangement 
of the Zn sites in Insugen (I) with respect to peptide 
chains B and D and the propanol associated with chain 
D ThrD27.
The Zn sites in Intergen (II) molecules 1 and 2 Figure 19d 
shows the electron density in the vicinity of Zn501 in the 
Intergen (II) structure molecule 1. Zn501 is coordinated 
by His10B Nε as usual and a single water molecule water 
617. There is no other solvate in this site. The Zn site in 
Intergen (II) molecule 2 is structured in the same way. 
Note: as previously stated the complete coordination 
sphere around the zinc ion is generated by application of 
the crystallographic three-fold symmetry.
Molecular dynamics
Insugen (I)
Introduction
As discussed previously in the ultra-high resolution X-ray 
structure of Insugen (I) in the internal disulphide bridge 
of chain C (CysC6–CysC11) CysC11 is disordered into 
two sites: A (80%) and B (20%), Figs. 13, 14a, b. However 
the corresponding disulphide bridge in chain A is not 
disordered, Fig. 15a, b. In this section molecular dynam-
ics calculations have been employed in order to investi-
gate and find a rational explanation for this difference.
Materials and methods
In order to prepare for the molecular dynamics (MD) 
simulations, two pdb files, Cys11_80percent.pdb and 
Cys11_20percent.pdb were generated from the origi-
nal high resolution crystal structure by editing the atom 
records for Cys11, generating two separate pdb files, one 
with the chain C CysC6–CysC11 disulphide in the major 
(80%) conformation, the other with the minor (20%) 
conformation. Following this, both structures, including 
water molecules in the crystal structure were subjected to 
energy minimisation using HyperChem 8  Professional(™) 
[29]. Energy minimisation was performed using the 
AMBER3 force field [30], using the Polak-Ribere conju-
gation gradient [31], with only the original contents of 
the crystal structure contained in a periodic box, since 
the object of the MD simulation was to explain the disor-
der in the original unit cell of the high resolution crystal 
structure, rather than a protein under normal solvated 
biological conditions.
As described below MD simulations were then per-
formed. Two MD simulations were run for each pdb file. 
The first simulation was run at 310 K for 300 ps, using an 
initial heat time of 5  ps, with data collected every 0.01 
picoseconds, with a time step of 0.002  ps, using NVT 
dynamics with a Berendsen thermostat [32]. The second 
simulation was run at a higher temperature of 320 K, an 
initial heat time of 2.5 ps. Data collection and time steps 
remained the same as the first simulation. The MD sim-
ulations were carried out using the leapfrog algorithm 
[33], with AMBER3 [30] being used as before. Data was 
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collected with respect to torsion angles for Cys6–Cys11 
S–S bonds from both chains A and C, along with root 
mean square deviations for the torsion angles. RMSD 
values at the end of the simulations were also collected 
for both insulin molecules in the crystal asymmetric unit 
(Table 4a, b).
Results
The results of both simulations showed several notable 
changes regarding torsion angle χ3 of the internal Cys6–
Cys11 disulphide bonds, where χ3 is defined by the atoms 
Cβ6–Sγ6–Sγ11–Cβ11. At the lower temperature (310 K) 
in the major conformation CysA6–CysA11 of chain A 
Fig. 19 a Insugen (I) electron density in the vicinity of Zn2100 (Zn2) in molecule 1: an acetate molecule acetate 2101 has been modelled in this 
site close to HisB10 in chain B. Drawn with WinCoot 0.7 [19]. b The Zn site in molecule 1 of Insugen (I). Zn2 is coordinated to His B10 Nε in chain B as 
usually observed in insulin structures (e.g Baker et al. [1]) and unexpectedly to a highly ordered acetate molecule acetate2101. Drawn with Accelrys 
Discovery Studio 3 [23]. c Insugen (I) structure electron density showing the vicinity of Zn4100 (Zn1) and HisD10 in chain D. Unlike chain B there 
is no acetate in this site. Two water molecules have been located whose equivalents are not present in the vicinity of Zn2100 (Zn2) which has the 
substituted acetate2101. Drawn with WinCoot 0.7 [19]. d Intergen (II) electron density in the vicinity of Zn501 in molecule 1 B‑chain. Both HisB10 Nε 
and water 617 coordinate Zn501. Water617 is the only coordinating water. There is no acetate molecule in this site. The same applies to site D. 
Drawn with WinCoot 0.7 [19]
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underwent a conformation change around 8 ps, decreas-
ing from about 120° to 50°, and then increased marginally 
before staying relatively constant between 60° and 80°. 
Chain C stayed relatively constant between 90° and 120°, 
Fig.  20a. The minor conformation for CysC6–CysC11 
of chain A stayed relatively constant between 100° and 
130°. CysC6–CysC11 of chain C, however, showed sev-
eral changes. At about 36–41  ps there is an increase in 
the torsion angle χ3, followed by a decrease (41–47 ps), 
then another increase (41–66 ps), then another decrease 
before χ3 remains relatively steady for the rest of the 
simulation at roughly −80° to −100°, Fig.  20b. For the 
simulations at 320 K, the most noticeable change for the 
major conformation of chain C showed a very sharp, but 
transient decrease to around 50°, between approx 2–4 ps, 
before increasing and remaining relatively constant for 
the rest of the stimulation, while chain A remained rel-
atively constant between 100° and 120°, Fig.  21a. Both 
Cys6–Cys11 of chains A and C stayed relatively constant 
for the minor conformation, Fig.  21b. Examination of 
the RMSD torsion angle kinetics for both the major and 
minor conformations of Cys6–Cys11 for the MD simu-
lations show that for the major conformation at 310  K, 
RMSD values are much higher for CysA6–CysA11 of 
chain A, Fig. 22a. However for the minor conformation 
at 310 K and the major conformation at 320 K, the RMSD 
values are much higher for CysC6–CysC11 in chain C for 
all or the majority of the simulation, Figs.  22b and 23a. 
For the minor conformation at 320 K, RMSD values start 
higher for Cys C, but then fall below Cys A after 60 ps, 
Fig. 23b.   
Intergen (II) 3W7Y
Materials and methods
The structure of Intergen (II) was also minimised using 
the method described above for Insugen (I), but was not 
split into two pdb files beforehand as no disordering was 
modelled for this structure, (Fig. 16). Following this, MD 
simulations were run at 310 K and 320 K, again using the 
methods described above for Insugen (I).
Results
The results for the simulations run at 310 K showed torsion 
angles χ3 for both Cys 6–Cys 11 in chains A and C largely 
remaining relatively steady around 80°–100°, except for 
some transient spikes above or below this range (Fig. 24a).
Upon repeating the simulations at the higher tem-
perature of 320 K, torsion angle χ3 for CysA6–Cysa11 in 
chain A started off mostly steady around 80°–100° up to 
about 35–55 ps, and then temporarily sharply decreased 
before increasing again and then remaining relatively 
constant and mostly steady around 80°–100° for the 
rest of the stimulation, except for some transient spikes. 
CysC6–CysC11 of chain C did not show any noticeable 
changes at the higher temperature, and remained rela-
tively constant around 80°–100°, except for some tran-
sient spikes, which is similar to the result obtained for 
Table 4 RSMD values (Å) for HR insulin structures after the 
MD simulation
Molecule 1 (chain A & B) Molecule 2 (chain C & D)
(a) Insugen (I)
 310 K
  Major 1.407 1.351
  Minor 1.794 1.987
 320 K
  Major 1.739 1.639
  Minor 2.003 2.155
(b) Intergen (II)
 310 K 1.501 2.125
 320 K 1.505 2.519
Fig. 20 a Plot of torsion angle χ3 changes for Cys6–Cys11 showing 
changes for the major conformation of HR insulin, Insugen (I) for the 
MD simulation carried out at 310 K. b Plot of torsion angle χ3 changes 
for Cys6–Cys11 showing changes for the minor conformation of HR 
insulin, Insugen (I) for the MD simulation carried out at 310 K
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310 K (Fig. 24b). The RMSD torsion angle kinetics sup-
port these changes, showing little difference between Cys 
6–Cys 11 in chains A and C over the course of the simu-
lation run at 310 K, but are much higher for Cys 6–Cys 
11 in chain A than for Cys 6–11 in chain C for the simu-
lation run at 320 K (Fig. 25a, b).
Conclusions
From the results of both the torsion angle plots and 
the RMSD kinetics for the Cys6–Cys11 SS bonds for 
Insugen (I), it is clear that both the Cys6–Cys11 inter-
nal disulphide bridges in chains A and C possess flex-
ibility. However the flexibility of Cys6–Cys11 of chain 
C appears to be much greater, as both the MD simu-
lations for the minor conformation at 310  K and the 
major conformation show times when the torsion angle 
of Cys6–Cys11 of chain C shows rapid decreases fol-
lowed by rapid increases. In contrast, Cys6–Cys11 of 
chain A only showed one major change, in the major 
conformation at 310 K, at all other times staying rela-
tively constant. The rapid changes in torsion angles 
shown by Cys6–Cys11 of chain C of Insugen (I) would 
appear to explain why it shows disorder in the original 
crystal structure.
From a structural point of view, examination of the 
secondary structures of chains A and C in the original 
crystal structure of Insugen (I) may provide an explana-
tion for this increased flexibility. The structure of these 
chains consists of a single loop between two α-helices. 
The length of the loop shows differences in chains C and 
A. In chain C the loop is long enough to contain both 
Cys residues involved in the internal disulphide bridge, 
whereas in chain A it is shorter and so one of the Cys res-
idues is located on an α-helix. The longer loop of chain C 
would be more flexible and therefore may possibly allow 
for more movement of the Cys residues involved in the 
disulphide bond. Over the course of the MD simulation 
Fig. 21 a Plot of torsion angle χ3 changes for Cys6–Cys11 for the 
major conformation in HR insulin, Insugen (I) for the MD simulation 
carried out at 320 K. b Plot of torsion angle χ3 changes for Cys6–
Cys11 for the minor conformation in HR insulin Insugen (I) for the MD 
simulation carried out at 320 K
Fig. 22 a Plot of RMSD kinetics of Cys6–Cys11 torsion angles χ3 for 
the HR insulin, Insugen (I) MD simulations carried out on the major 
conformation of chain C Cys6–Cys11 at 310 K. b Plot of RMSD kinetics 
of Cys6–Cys11 torsion angles χ3 for the HR insulin Insugen (I) MD 
simulations carried out on the major conformation of chain C Cys6–
Cys11 at 320 K
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changes in secondary structure occur, most noticeably in 
chain C, with significant portions becoming converted 
to coils, which may further affect flexibility (Fig.  26). In 
contrast, the results for torsion angle changes and RMSD 
kinetics for Intergen (II) at 320  K suggest that for this 
structure, Cys 6–11 of chain A possess greater flexibil-
ity than Cys 6–11 of chain A. However, the difference in 
flexibility would not seem to be as great for Insugen (I).
Overall conclusions from the molecular dynamics study
From the results of both the torsion angle plots and 
the RMSD kinetics for the Cys6–Cys11 S–S bonds of 
Insugen (I), it is clear that both the Cys6–Cys11 inter-
nal disulphide bridges in chains A and C of possess flex-
ibility. However the flexibility of Cys6–Cys11 of chain C 
appears to be much greater, as both the MD simulations 
for the minor conformation at 310 K and the major con-
formation show times when the torsion angle of Cys6–
Cys11 of chain C shows rapid decreases followed by 
rapid increases. In contrast, Cys6–Cys11 of chain A only 
showed one major change, in the major conformation at 
310 K, at all other times staying relatively constant. The 
rapid changes in torsion angles shown by Cys6–Cys11 
of chain C of Insugen (I) would appear to explain why it 
shows disorder in the original crystal structure.
From a structural point of view, examination of the 
secondary structures of chains A and C of Insugen (I) in 
the original crystal structure may provide an explana-
tion for this increased flexibility. The structure of these 
chains consists of a single loop between two α-helices. 
The length of the loop shows differences in chains C and 
Fig. 23 a Plot of RMSD kinetics of Cys6–Cys11 torsion angles χ3 for 
the HR insulin, Insugen (I) MD simulations carried out on the minor 
conformation of chain C Cys6–Cys11 at 310 K. b Plot of RMSD kinetics 
of Cys6–Cys11 torsion angles χ3 for the HR insulin Insugen (I) MD 
simulations carried out on the minor conformation of chain C Cys6–
Cys11 at 320 K
Fig. 24 a Plot of torsion angle χ3 changes for Cys6–Cys11 in chains 
A and C in HR insulin Intergen (II) 3W7Y for the MD simulation carried 
out at 310 K. b Plot of RMSD kinetics of Cys6–Cys11 torsion angles χ3 
for the HR insulin Intergen (II) 3W7Y in chains A and C, respectively. 
MD simulations carried out at 310 K
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A. In chain C the loop is long enough to contain both 
Cys residues involved in the internal disulphide bridge, 
whereas in chain A it is shorter and so one of the Cys res-
idues is located on an α-helix. The longer loop of chain C 
would be more flexible and therefore may possibly allow 
for more movement of the Cys residues involved in the 
disulphide bond. Over the course of the MD simulation 
changes in secondary structure occur in Insugen (I), most 
noticeably in chain C, with significant portions becoming 
converted to coils, which may further affect flexibility.
Discussion
General comments and further selected examples
The ultra-high resolution X-ray structures of two forms 
of human recombinant insulin, Insugen (I) and Inter-
gen (II), has revealed several quite unexpected and 
previously unpredicted features. Both Insugen (I) and 
Intergen (II) structures exhibit structural features that 
can be described as: (a) highly ordered; (b) clear and 
resolved double conformations; (c) badly disordered. 
The assembled molecule comprises polypeptide chains 
A, B, C and D where A and C are sequence equivalent, 
as are B and D. It is somewhat surprising that the occur-
rence of structural features (a), (b) and (c) between say 
Insugen (I) chains A and C is by no means one to one 
but rather almost lacking in correspondence. This obser-
vation applies to all pairs of like polypeptide chains in 
both Insugen (I) and Intergen (II) and to all pairs of like 
polypeptide chains one from Insugen (I) and one from 
Intergen (II). It would be of interest (1) to find expla-
nations for these differences and (2) to know whether 
they affect the therapeutic properties of these prepara-
tions? As described in “General comments and further 
selected examples” below why a given residue should be 
perfectly ordered in one structure and badly disordered 
Fig. 25 a Plot of torsion angle χ3 changes for Cys6–Cys11 in chains 
A and C in HR insulin Intergen (II) 3W7Y for the MD simulation carried 
out at 320 K. b Plot of RMSD kinetics of Cys6–Cys11 torsion angles χ3 
for the HR insulin Intergen (II) 3W7Y in chains A and C, respectively. 
MD simulations carried out at 320 K
Fig. 26 HR insulin(Insugen I) comparison of secondary structures 
of chains C and A of the major conformation, showing the starting 
structure (with Cys6–Cys11 S–S bridge shown) and then after MD 
simulation for 300 ps at 310 and 320 K. Drawn with Swiss‑PdbViewer 
(Deep View) [36]
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in the other? With respect to question (1) the possibili-
ties include (a) method of preparation including folding 
of the recombinant amino acid-chains and (b) the forces 
in play when the crystal is cryo cooled prior to X-ray data 
collection. With respect to question (2) it is well known 
that differences in the form of a therapeutic insulin prep-
aration with respect to the naturally occurring insulin 
can induce the production of antibodies in patients. No 
such indication has been noted with respect to the wide-
spread use of either Insugen (I) or Intergen (II) but is 
nevertheless a possibility which should be borne in mind. 
It may be possible to use molecular dynamics simulations 
further to resolve some of these considerations.
Previous studies: (i) that of Baker et al. [1] at room tem-
perature and a resolution of 1.5 Å on porcine insulin and 
(ii) that of Smith, Pangborn and Blessing on a commer-
cially available biosynthetic form of  T6 human insulin 
(Lilly Research Laboratories) at 120  K and 1.0  Å resolu-
tion [24] have revealed significant differences in a num-
ber of the individual amino acid residue conformations 
between the two structures. The level of refinement 
achieved in these two analyses, as is also the case with 
the low temperature structure of Intergen (II) HR insu-
lin, as judged by the final R values (0.153, 0.183 and 0.168, 
respectively) are all inferior to that achieved here with the 
Insugen (I) HR insulin (0.1112). Interestingly Smith et al. 
[34] list seven side-chains in the porcine room tempera-
ture structure [1] at 1.5 Å resolution and nine side-chains 
in their 1.0 Å human insulin structure as having two dis-
tinct conformations. The residues involved are: porcine 
GlnB4, ValB12, GluB21, ArgB22, ThrB27 and LysD29; 
human GlnB4, ValB12, GluB17, GluD21, GluC5, LeuC16, 
ValD12, ValD18 and GluD21. Only two residues are in 
common in this list: GlnB4 and ValB12. This result fol-
lows the trend reported here for Insugen (I) and Intergen 
(II) that correspondence between the two structures with 
respect to multiple or disordered conformations does not 
follow any fixed pattern. However, interestingly, reference 
to Fig. 11 reveals that in both Insugen (I) and Intergen (II) 
GlnB4 and ValB12 presented problems in the interpreta-
tion of their electron densities. Of the other residues in 
the above porcine list some are clear single conformations 
and others are problematic in either Insugen (I) or Inter-
gen (II). Similar comments apply with respect to the above 
list for biosynthetic form of  T6 human insulin. GlnB4 and 
ValB12 are the only residues in all four of these insulin 
structures that presented problems. According to Fig.  2 
ValB12 is significantly involved in the interaction of insu-
lin with its receptor.
PheB24 and PheB25 in Insugen (I) and Intergen (II)
A significant example of structural differences in the 
ultra-high resolution 100  K structures of Insugen (I) 
and Intergen (II) can be found in the phenylalanine resi-
dues PheB24 and B25 (see Fig. 11). As stated previously 
in “Introduction” these residues, amongst others, are 
important for insulin receptor binding [6]. As reported 
by Baker et  al. [1] changes in biological activity occur 
when these residues are modified. Figures  27a,  b show 
the electron density in Insugen (I) for residues PheB24 
and B25, respectively while Fig.  28a, b show the electron 
density in Intergen (II) for the same residues. 
The significant observation here is the extremely poor 
electron density for PheB25 in Insugen (I) which has 
been modelled as disordered with two distinct conforma-
tions, as opposed to PheB24 in Insugen (I) and PheB24 
and PheB25 in Intergen (II) which are all excellent exam-
ples of strong, clearly resolved single conformation elec-
tron density. It is of interest to note that PheB25 in the 
X-ray structure of porcine insulin [1] has comparatively 
weak electron density corresponding to a single well 
defined conformation but with one missing atom on the 
phenyl ring (see also Footnote 1; Additional file 1: Figure 
S6a) and PheB24 is in completely well-defined electron 
Fig. 27 a Electron density in the Insugen (I) structure for PheB24, 
an example of a clear single highly resolved amino acid residue. b 
Electron density in the Insugen (I) structure for PheB25, an example of 
very poor density modelled as a doubly disordered acid residue. This 
result is surprising in view of the high order observed in PheB24 (a)
Page 24 of 26Lisgarten et al. Chemistry Central Journal  (2017) 11:73 
density as are PheD24 and PheD25. What is probably 
most surprising is that while Insugen (I) PheD25 has 
strong electron density corresponding to a single ordered 
conformation, as is also the case for Intergen (II) and por-
cine insulin [2], the conformation for Insugen (I) PheD25 
uniquely corresponds to that of the ordered porcine B 
conformation, not the porcine D conformation as dis-
played by the other two PheD conformations (see also 
Additional file  1: Text S6, Figure S6a–h). It is planned 
to investigate the situation with respect to PheB24 and 
PheB25 in Insugen (I) and Intergen (II) using molecular 
dynamics as described in “Molecular dynamics” for the 
Sγ6–Sγ11 disulphides.
Intergen (II) structure: chain C(3) S–S bridge between Sγ6–
Sγ11
The intra-chain S–S bridge in chain C(3) Cys6–Cys11 has 
been observed in Insugen (I) to exhibit two ordered con-
formations. Cys6 occupies a single site while Cys11 occu-
pies two sites with relative occupancies of 0.8 and 0.2, 
respectively. The geometry and all other refinement char-
acteristics of this bifurcated cysteine bridge are of excel-
lent quality as discussed previously. The corresponding 
S–S bridge in Insugen (I) chain A(1) is completely 
ordered which again poses a question about the origin 
of the distinction between the two molecular dynamics 
simulations. Molecular dynamics studies  have provided 
rationale in answer to this question. In fact the difference 
in the disulphides A6–A11 and C6–C11 may be further 
explained by the difference in solvent exposure. A6 is less 
than 4  Å from the nearest water solvent molecule and 
there are several waters modelled in that area which may 
give greater conformational flexibility to the region. C6 is 
in a hydrophobic pocket and consequently the disulphide 
may be more restricted by that environment. This is sup-
ported both by the fact that the section of chain B near 
this part of the molecule is also disordered. With refer-
ence to Intergen (II) the corresponding S–S bridge in 
chain A(1) is also completely singular and ordered. This 
S–S bridge in chain C(3) as observed by inspection of 
PDB 3W7Y has been modelled as a single ordered con-
formation. However, as discussed previously, there is evi-
dence in the electron density (Fig. 16) that this S–S bridge 
is actually bifurcated as in the corresponding S–S bridge 
in Insugen (I). S–S bridges with ordered double confor-
mations have been previously reported. For example 
Cys14–Cys 38 in the ultra-high resolution (0.86  Å) low 
temperature, synchrotron structure of bovine pancreatic 
trypsin inhibitor [25] is very similar to Cys6–Cys11 in 
Insugen (I).
Solvated propanol
The ultra-high resolution Insugen (I) X-ray structure 
was found to include an ordered solvated propanol mol-
ecule which forms H-bonds with the prominent OG1A of 
ThrD27 in chain D(4) and two water molecules. The elec-
tron density for this solvate is clear and the geometry of 
the refined propanol is excellent. There is no solvated pro-
panol in Insugen (I) chain B(2) or in either chain B or D in 
Intergen (II). These differences again offer a challenge to a 
rational explanation. The origin of the solvated propanol 
in Insugen (I) may be questioned. However it is known 
that propanol is a minor component used in the manufac-
turing process and is most likely to have been introduced 
into the protein at some stage of the synthesis procedure. 
To the best of our knowledge no other insulin structure 
has been shown to include structurally ordered propanol.
Fig. 28 a Electron density in the Intergen (II) structure for PheB24, 
an example of a clear single highly resolved amino acid residue as in 
Insugen (I), Fig. 27a. b Electron density in the Intergen (II) structure 
for PheB25. Unlike PheB25 in Insugen (I), Fig. 27b which has very 
weak electron density, this is another example of a clear single highly 
resolved amino acid residue as in Insugen (I) PheB24, Fig. 27a and 
Intergen (II) Phe24, (a)
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The Zn sites
Insugen (I) and Intergen (II) have been synthesised to 
include the essential Zn ions present in naturally occur-
ring insulins. The Zn ions are an essential feature in the 
formation of the crystal structure and are located on a 
crystallographic three-fold axis.
The Zn site in Insugen (I) molecule 1
The electron density in the vicinity of Zn2 in molecule 
1 revealed an unexpected feature which was shown to 
be a solvated acetate molecule. Zn2 is coordinated to 
both His10B Nε in chain B and an oxygen atom of the 
acetate. It is most likely that the presence of solvated 
acetate originated during crystallization. There are 
no other solvated acetate sites in either Insugen (I) or 
Intergen (II).
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